Biosynth Extends its Offering to Multi-Kilogram GMP Peptide Synthesis through the Acquisition of Pepceuticals
Advertisement
Biosynth announced the acquisition of Pepceuticals, a UK producer of synthetic peptides with multi-kilogram GMP facilities and fill-finish capabilities designed to support customers from clinical trials to commercial supply.
Dr. Urs Spitz, CEO and President of Biosynth, commented, “We are very excited for Pepceuticals to be joining Biosynth. The Pepceuticals team has great expertise in optimizing the production of peptides and working at GMP and larger scales, making it a natural fit for Biosynth as we round out our peptide offering. "
Ehab Alramahy, Senior Vice President, Head of Peptide Division, added “The acquisition of Pepceuticals into the Biosynth family strengthens our position in the peptide field. As we've built the peptide division, our goal has always been to offer a seamless, comprehensive service to our customers. The acquisition represents an important step which allows us to extend our support to clinical trials and commercial supply.”
“Joining the Biosynth Group marks the start of an exciting chapter for our team.” Dr. Kamal Badiani, Managing Director of Pepceuticals, states, “We look forward to working together, combining our expertise and enhancing our offering to our customers. We are excited to join Biosynth and provide leading peptide manufacturing services.”
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Intercell reports Phase II Study Results of its Vaccine Enhancement Patch for Pandemic Influenza
BTG: Study Shows Abiraterone Can Successfully Treat Aggressive, Chemotherapy-Resistant Prostate Cancer
SEQUENOM and National Institutes of Health Expand Relationship for Gene Expression - Agreement Builds on Success of Previous SNP Genotyping Research
Muscle-Targeted Gene Therapy Reverses Rare Muscular Dystrophy in Mice
Study finds 'mad cow disease' in cattle can spread widely in ANS before detectable in CNS
Simple and Fast Method for Radiolabelling Antibodies against Breast Cancer - Using UV light, radiolabelled antibodies can be produced in just 15 minutes
Bioactive natural compounds for the fight against cancer - New synthesis route manages without toxic and expensive oxidizing agent and at the same time proves to be much more efficient
Genzyme Receives Approval for Additional Manufacturing at Ireland Plant - Thymoglobulin Fill/Finishing to Begin Immediately
A fruit a day may keep Alzheimer's at bay, suggests new Cornell study
Ear wax as a possible screening medium for Parkinson’s disease
BASF invests in biotechnology start-up Bota Bio - Bota Bio’s next-generation industrial biology platform is a combination of computation and cutting-edge biotechnology
